Report cover image

Global Varicella Attenuated Live Vaccine Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 197 Pages
SKU # APRC20283977

Description

Summary

According to APO Research, The global Varicella Attenuated Live Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Varicella Attenuated Live Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Varicella Attenuated Live Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Varicella Attenuated Live Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Varicella Attenuated Live Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Varicella Attenuated Live Vaccine include Changchun Changsheng Life Sciences Limited, Keygen, BCHT, Shanghai Institute, Shanghai Rongsheng Biotech, Merck, GSK, Green Cross and Biken, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Varicella Attenuated Live Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Varicella Attenuated Live Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Varicella Attenuated Live Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Varicella Attenuated Live Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Varicella Attenuated Live Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Varicella Attenuated Live Vaccine sales, projected growth trends, production technology, application and end-user industry.

Varicella Attenuated Live Vaccine Segment by Company

Changchun Changsheng Life Sciences Limited
Keygen
BCHT
Shanghai Institute
Shanghai Rongsheng Biotech
Merck
GSK
Green Cross
Biken
Varicella Attenuated Live Vaccine Segment by Type

Monovalent Vaccine
Combination Vaccine
Varicella Attenuated Live Vaccine Segment by Application

Kids Injection
Adults Injection
Varicella Attenuated Live Vaccine Segment by Region

North America
United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Attenuated Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Varicella Attenuated Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Attenuated Live Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Varicella Attenuated Live Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Varicella Attenuated Live Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Varicella Attenuated Live Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Varicella Attenuated Live Vaccine Market by Type
1.2.1 Global Varicella Attenuated Live Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Monovalent Vaccine
1.2.3 Combination Vaccine
1.3 Varicella Attenuated Live Vaccine Market by Application
1.3.1 Global Varicella Attenuated Live Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Kids Injection
1.3.3 Adults Injection
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Varicella Attenuated Live Vaccine Market Dynamics
2.1 Varicella Attenuated Live Vaccine Industry Trends
2.2 Varicella Attenuated Live Vaccine Industry Drivers
2.3 Varicella Attenuated Live Vaccine Industry Opportunities and Challenges
2.4 Varicella Attenuated Live Vaccine Industry Restraints
3 Global Market Growth Prospects
3.1 Global Varicella Attenuated Live Vaccine Revenue Estimates and Forecasts (2020-2031)
3.2 Global Varicella Attenuated Live Vaccine Revenue by Region
3.2.1 Global Varicella Attenuated Live Vaccine Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Varicella Attenuated Live Vaccine Revenue by Region (2020-2025)
3.2.3 Global Varicella Attenuated Live Vaccine Revenue by Region (2026-2031)
3.2.4 Global Varicella Attenuated Live Vaccine Revenue Market Share by Region (2020-2031)
3.3 Global Varicella Attenuated Live Vaccine Sales Estimates and Forecasts 2020-2031
3.4 Global Varicella Attenuated Live Vaccine Sales by Region
3.4.1 Global Varicella Attenuated Live Vaccine Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Varicella Attenuated Live Vaccine Sales by Region (2020-2025)
3.4.3 Global Varicella Attenuated Live Vaccine Sales by Region (2026-2031)
3.4.4 Global Varicella Attenuated Live Vaccine Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Varicella Attenuated Live Vaccine Revenue by Manufacturers
4.1.1 Global Varicella Attenuated Live Vaccine Revenue by Manufacturers (2020-2025)
4.1.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Varicella Attenuated Live Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Varicella Attenuated Live Vaccine Sales by Manufacturers
4.2.1 Global Varicella Attenuated Live Vaccine Sales by Manufacturers (2020-2025)
4.2.2 Global Varicella Attenuated Live Vaccine Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Varicella Attenuated Live Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Varicella Attenuated Live Vaccine Sales Price by Manufacturers (2020-2025)
4.4 Global Varicella Attenuated Live Vaccine Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Varicella Attenuated Live Vaccine Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Varicella Attenuated Live Vaccine Manufacturers, Product Type & Application
4.7 Global Varicella Attenuated Live Vaccine Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Varicella Attenuated Live Vaccine Market CR5 and HHI
4.8.2 2024 Varicella Attenuated Live Vaccine Tier 1, Tier 2, and Tier 3
5 Varicella Attenuated Live Vaccine Market by Type
5.1 Global Varicella Attenuated Live Vaccine Revenue by Type
5.1.1 Global Varicella Attenuated Live Vaccine Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Varicella Attenuated Live Vaccine Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2020-2031)
5.2 Global Varicella Attenuated Live Vaccine Sales by Type
5.2.1 Global Varicella Attenuated Live Vaccine Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Varicella Attenuated Live Vaccine Sales by Type (2020-2031) & (K Units)
5.2.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2020-2031)
5.3 Global Varicella Attenuated Live Vaccine Price by Type
6 Varicella Attenuated Live Vaccine Market by Application
6.1 Global Varicella Attenuated Live Vaccine Revenue by Application
6.1.1 Global Varicella Attenuated Live Vaccine Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Varicella Attenuated Live Vaccine Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2020-2031)
6.2 Global Varicella Attenuated Live Vaccine Sales by Application
6.2.1 Global Varicella Attenuated Live Vaccine Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Varicella Attenuated Live Vaccine Sales by Application (2020-2031) & (K Units)
6.2.3 Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2020-2031)
6.3 Global Varicella Attenuated Live Vaccine Price by Application
7 Company Profiles
7.1 Changchun Changsheng Life Sciences Limited
7.1.1 Changchun Changsheng Life Sciences Limited Comapny Information
7.1.2 Changchun Changsheng Life Sciences Limited Business Overview
7.1.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolio
7.1.5 Changchun Changsheng Life Sciences Limited Recent Developments
7.2 Keygen
7.2.1 Keygen Comapny Information
7.2.2 Keygen Business Overview
7.2.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Keygen Varicella Attenuated Live Vaccine Product Portfolio
7.2.5 Keygen Recent Developments
7.3 BCHT
7.3.1 BCHT Comapny Information
7.3.2 BCHT Business Overview
7.3.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 BCHT Varicella Attenuated Live Vaccine Product Portfolio
7.3.5 BCHT Recent Developments
7.4 Shanghai Institute
7.4.1 Shanghai Institute Comapny Information
7.4.2 Shanghai Institute Business Overview
7.4.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolio
7.4.5 Shanghai Institute Recent Developments
7.5 Shanghai Rongsheng Biotech
7.5.1 Shanghai Rongsheng Biotech Comapny Information
7.5.2 Shanghai Rongsheng Biotech Business Overview
7.5.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolio
7.5.5 Shanghai Rongsheng Biotech Recent Developments
7.6 Merck
7.6.1 Merck Comapny Information
7.6.2 Merck Business Overview
7.6.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Merck Varicella Attenuated Live Vaccine Product Portfolio
7.6.5 Merck Recent Developments
7.7 GSK
7.7.1 GSK Comapny Information
7.7.2 GSK Business Overview
7.7.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 GSK Varicella Attenuated Live Vaccine Product Portfolio
7.7.5 GSK Recent Developments
7.8 Green Cross
7.8.1 Green Cross Comapny Information
7.8.2 Green Cross Business Overview
7.8.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Green Cross Varicella Attenuated Live Vaccine Product Portfolio
7.8.5 Green Cross Recent Developments
7.9 Biken
7.9.1 Biken Comapny Information
7.9.2 Biken Business Overview
7.9.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Biken Varicella Attenuated Live Vaccine Product Portfolio
7.9.5 Biken Recent Developments
8 North America
8.1 North America Varicella Attenuated Live Vaccine Market Size by Type
8.1.1 North America Varicella Attenuated Live Vaccine Revenue by Type (2020-2031)
8.1.2 North America Varicella Attenuated Live Vaccine Sales by Type (2020-2031)
8.1.3 North America Varicella Attenuated Live Vaccine Price by Type (2020-2031)
8.2 North America Varicella Attenuated Live Vaccine Market Size by Application
8.2.1 North America Varicella Attenuated Live Vaccine Revenue by Application (2020-2031)
8.2.2 North America Varicella Attenuated Live Vaccine Sales by Application (2020-2031)
8.2.3 North America Varicella Attenuated Live Vaccine Price by Application (2020-2031)
8.3 North America Varicella Attenuated Live Vaccine Market Size by Country
8.3.1 North America Varicella Attenuated Live Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Varicella Attenuated Live Vaccine Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Varicella Attenuated Live Vaccine Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Varicella Attenuated Live Vaccine Market Size by Type
9.1.1 Europe Varicella Attenuated Live Vaccine Revenue by Type (2020-2031)
9.1.2 Europe Varicella Attenuated Live Vaccine Sales by Type (2020-2031)
9.1.3 Europe Varicella Attenuated Live Vaccine Price by Type (2020-2031)
9.2 Europe Varicella Attenuated Live Vaccine Market Size by Application
9.2.1 Europe Varicella Attenuated Live Vaccine Revenue by Application (2020-2031)
9.2.2 Europe Varicella Attenuated Live Vaccine Sales by Application (2020-2031)
9.2.3 Europe Varicella Attenuated Live Vaccine Price by Application (2020-2031)
9.3 Europe Varicella Attenuated Live Vaccine Market Size by Country
9.3.1 Europe Varicella Attenuated Live Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Varicella Attenuated Live Vaccine Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Varicella Attenuated Live Vaccine Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Netherlands
9.3.9 Nordic Countries
10 China
10.1 China Varicella Attenuated Live Vaccine Market Size by Type
10.1.1 China Varicella Attenuated Live Vaccine Revenue by Type (2020-2031)
10.1.2 China Varicella Attenuated Live Vaccine Sales by Type (2020-2031)
10.1.3 China Varicella Attenuated Live Vaccine Price by Type (2020-2031)
10.2 China Varicella Attenuated Live Vaccine Market Size by Application
10.2.1 China Varicella Attenuated Live Vaccine Revenue by Application (2020-2031)
10.2.2 China Varicella Attenuated Live Vaccine Sales by Application (2020-2031)
10.2.3 China Varicella Attenuated Live Vaccine Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Varicella Attenuated Live Vaccine Market Size by Type
11.1.1 Asia Varicella Attenuated Live Vaccine Revenue by Type (2020-2031)
11.1.2 Asia Varicella Attenuated Live Vaccine Sales by Type (2020-2031)
11.1.3 Asia Varicella Attenuated Live Vaccine Price by Type (2020-2031)
11.2 Asia Varicella Attenuated Live Vaccine Market Size by Application
11.2.1 Asia Varicella Attenuated Live Vaccine Revenue by Application (2020-2031)
11.2.2 Asia Varicella Attenuated Live Vaccine Sales by Application (2020-2031)
11.2.3 Asia Varicella Attenuated Live Vaccine Price by Application (2020-2031)
11.3 Asia Varicella Attenuated Live Vaccine Market Size by Country
11.3.1 Asia Varicella Attenuated Live Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Varicella Attenuated Live Vaccine Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Varicella Attenuated Live Vaccine Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Varicella Attenuated Live Vaccine Market Size by Type
12.1.1 SAMEA Varicella Attenuated Live Vaccine Revenue by Type (2020-2031)
12.1.2 SAMEA Varicella Attenuated Live Vaccine Sales by Type (2020-2031)
12.1.3 SAMEA Varicella Attenuated Live Vaccine Price by Type (2020-2031)
12.2 SAMEA Varicella Attenuated Live Vaccine Market Size by Application
12.2.1 SAMEA Varicella Attenuated Live Vaccine Revenue by Application (2020-2031)
12.2.2 SAMEA Varicella Attenuated Live Vaccine Sales by Application (2020-2031)
12.2.3 SAMEA Varicella Attenuated Live Vaccine Price by Application (2020-2031)
12.3 SAMEA Varicella Attenuated Live Vaccine Market Size by Country
12.3.1 SAMEA Varicella Attenuated Live Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Varicella Attenuated Live Vaccine Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Varicella Attenuated Live Vaccine Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Varicella Attenuated Live Vaccine Value Chain Analysis
13.1.1 Varicella Attenuated Live Vaccine Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Varicella Attenuated Live Vaccine Production Mode & Process
13.2 Varicella Attenuated Live Vaccine Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Varicella Attenuated Live Vaccine Distributors
13.2.3 Varicella Attenuated Live Vaccine Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.